BioXcel Q3 net loss $30.9M; plans sNDA for IGALMI at-home use in Q1 2026

BioXcel Therapeutics, Inc.

2025-Q3 EPS reported -$6.38 revenue$386,000

Net revenue of $98K from IGALMI, down from $214K YoY; cost of goods sold fell to $11K.
Net loss widened to $30.9M ($14.2M operating loss) from $13.7M loss a year ago; operating cash use $18.8M.
R&D expense rose to $8.7M (up $3.6M) due to SERENITY At-Home trial; SG&A fell to $5.4M.
Cash and equivalents $37.3M at Sep 30; raised $4.9M post-quarter via ATM.
Plans sNDA submission in early Q1 2026 for IGALMI at-home agitation treatment; revised addressable market to 57-77M annual episodes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.